Evidence map›Paper›PMID 35088206›Full record

ArticleCancer causes & control : CCC2022

A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.

Jaleesa Moore, Tuya Pal, Alicia Beeghly-Fadiel, Mary Kay Fadden, Heather M Munro, Steffie-Ann Dujon, Sonya Reid, Ann Tezak, Miaya Blasingame, Jeania Ware and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cancer causes & control : CCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Jaleesa MooreDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Tuya PalDivision of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Alicia Beeghly-FadielDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Mary Kay FaddenDepartment of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA.
Heather M MunroVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA.
Steffie-Ann DujonDepartment of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA.
Sonya ReidVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Ann TezakDivision of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Miaya BlasingameVanderbilt University School of Medicine, Nashville, TN, USA.
Jeania WareMeharry Medical College, Nashville, TN, USA.
William J BlotDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Maureen Sanderson *Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Loren Lipworth *Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. loren.lipworth@vumc.org.ORCID http://orcid.org/0000-0001-7528-9775
Vanderbilt University Medical Center · USMeharry Medical College · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Southern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Southern Community Cohort StudyU01CA202979 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., SHRUBSOLE, MARTHA J. · 2016 to 2025
$22.0M
TrainingU54CA163072 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Karen Marie Winkfield · 2011 to 2026
$20.1M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI BALLARD, BILLY RAY · 2011 to 2025
$18.8M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Breast Cancer genetic study in African-ancestry populationsR01CA202981 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wei Zheng · 2016 to 2026
$14.1M
The Nashville Breast Health StudyR01CA100374 · NCI · VANDERBILT UNIVERSITY · PI ZHENG, WEI · 2004 to 2009
$4.2M
Vanderbilt Training Program in Molecular and Genetic Epidemiology of CancerT32CA160056 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Xiao-Ou Shu · 2017 to 2026
$3.8M
Understanding breast cancer subtypes in Black womenR03CA192214 · NCI · MEHARRY MEDICAL COLLEGE · PI SANDERSON, MAUREEN · 2015 to 2016
$157k
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1TR000445NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS P50CA098131NCI NIH HHS R01 CA092447NCI NIH HHS R01CA092447NCI NIH HHS R01 CA100374NCI NIH HHS R01CA100374NCI NIH HHS R01 CA202981NCI NIH HHS R01CA202981NCI NIH HHS R03 CA192214NCI NIH HHS R03CA192214NCI NIH HHS T32 CA160056NCI NIH HHS U01 CA202979NCI NIH HHS U01CA202979NCI NIH HHS U54 CA163069NCI NIH HHS U54CA163069NCI NIH HHS U54 CA163072NCI NIH HHS U54CA163072NIH HHS T32 CA160056vanderbilt-ingram cancer center P30CA068485
6 · The paper itself

Abstract

purposeTo evaluate the association between obesity and the relative prevalence of tumor subtypes among Black women with breast cancer (BC).

methodsWe conducted a pooled case-only analysis of 1,793 Black women with invasive BC recruited through three existing studies in the southeastern US. Multivariable case-only polytomous logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between obesity, measured by pre-diagnostic body mass index (BMI), and human epidermal growth factor receptor 2 + (HER2 +) and triple negative BC (TNBC) subtype relative to hormone receptor (HR) + /HER2- status (referent).

resultsAmong 359 premenopausal women, 55.4% of cases were HR + /HER2 -, 20.1% were HER2 + , and 24.5% were TNBC; corresponding percentages among 1,434 postmenopausal women were 59.3%, 17.0%, and 23.6%. Approximately, 50-60% of both pre- and postmenopausal women were obese (BMI > 30 kg/m

conclusionIn this large study of Black women with BC, there was no evidence of heterogeneity of BMI by BC subtype.

Indexed as

Black or African AmericanBreast NeoplasmsObesityTriple Negative Breast NeoplasmsBody Mass IndexErb-b2 Receptor Tyrosine KinasesFemaleHumansPremenopauseReceptors, ProgesteroneRisk FactorsSoutheastern United StatesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneBlack WomenBreast cancerBreast cancer subtypesObesityPostmenopausalPremenopausal

Identifiers

PMID35088206
PMCPMC9006670
OpenAlexW4210626786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.